PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Zidovudine - Prevention of HIV vertical transmission

PAD Profile : Zidovudine - Prevention of HIV vertical transmission

Keywords :
antiviral, vertical transmission, HIV prophylaxis, mothers, babies, peri-natal
Brand Names Include :
Retrovir

Traffic Light Status

Status 1 of 1.

Status :
Red
Important
Formulations :
  • Not Specified
Important Information :
Restricted use - prevention of vertical transmission in babies born to HIV-positive mothers. Use as recommended in BHIVA guidelines
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
R
NHSE
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
04 September 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

These drugs falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication

Associated BNF Codes

05. Infections
05.03.01. HIV infection
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More